McDermott + Bull has successfully placed Cyril Allouche as the Chief Financial Officer at Avellino. Cyril will lead the organization as they complete their pivot to COVID testing and begin their transformation into a world-class genetics and genomics leader. He will also be responsible for preparing the company for an eventual initial public offering.
Cyril is a career finance executive and has spent much of his career in the life sciences space. He has led organizations through both pre- and post-IPO environments, bringing a unique perspective to this role. Throughout his career, he has acquired experience in financial restructuring, developing teams post-IPO, and driving extremely fast growth through both organic means and acquisition.
Avellino is building a world-class platform for the effective and rapid analysis of genes associated with important medical conditions. It was the first lab in the United States performing commercial genetic testing for Corneal Dystrophy. Their advanced genetic diagnostics systems provide fast, safe, and affordable evaluations of an individual’s genetic predisposition for specific medical conditions.